Allianz Asset Management GmbH Buys 82,065 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Allianz Asset Management GmbH increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 306.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,871 shares of the biopharmaceutical company’s stock after acquiring an additional 82,065 shares during the quarter. Allianz Asset Management GmbH owned about 0.08% of Alnylam Pharmaceuticals worth $25,618,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $61,160,000. Strategic Financial Concepts LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $41,529,000. Eventide Asset Management LLC raised its holdings in Alnylam Pharmaceuticals by 157.9% during the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after acquiring an additional 137,333 shares during the period. Los Angeles Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares in the last quarter. Finally, Telemark Asset Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $27,503,000. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,986 shares of company stock valued at $20,397,849. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Down 0.7 %

ALNY stock opened at $248.94 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market capitalization of $32.23 billion, a PE ratio of -114.72 and a beta of 0.35. The firm has a 50 day moving average of $254.24 and a 200 day moving average of $262.90.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ALNY shares. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. HC Wainwright lifted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a report on Monday. Piper Sandler restated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $303.83.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.